• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Impact of Approved Drug Labeling on Chronic Opioid Therapy Part 15 Meeting

The U.S. Food and Drug Administration (FDA) is announcing a public hearing to obtain information, particularly scientific evidence, such as study data or peer-reviewed analyses, on issues pertaining to the use of opioid drugs in the treatment of chronic pain. These issues include: diagnosis and understanding of patient pain, understanding and adhering to the labels of pain-treating products, limiting opioid prescriptions and use, and abuse and misuse of opioid medicines.

Date(s): February 7-8, 2013 from 9:00 a.m. to 4:00 p.m.

Location: Bethesda Marriott
5151 Pooks Hill Road
Bethesda, MD 20814

Please Note: Venue will charge attendees to park on site.